401 Episoder

  1. Episode 163: The Uromigos Debate - Treatment of favorable risk renal cancer

    Publisert: 21.3.2022

  2. Episode 162: Debate - Adjuvant nivolumab for bladder cancer

    Publisert: 14.3.2022

  3. Episode 161: Platinum eligibility in urothelial cancer

    Publisert: 7.3.2022

  4. Episode 160: APCCC - PMSA PET as a diagnostic

    Publisert: 28.2.2022

  5. Episode 159: ASCO GU 2022 Adjuvant and neoadjuvant therapy in renal cancer

    Publisert: 19.2.2022

  6. Episode 158: ASCO GU 2022 PROpel Phase III olaparib and abiraterone in renal cancer

    Publisert: 19.2.2022

  7. Episode 156: ASCO GU 2022 1st line olaparib and durvalumab in bladder cancer

    Publisert: 18.2.2022

  8. Episode 157: ASCO GU 2022 Sasatuzimab and pembrolizumab in bladder cancer

    Publisert: 18.2.2022

  9. Episode 154: ASCO GU 2022 MAGNITUDE trial of niraparib and abiraterone in metastatic CRPC

    Publisert: 17.2.2022

  10. Episode 155: ASCO GU 2022 ARASENS trial of darolutamide plus chemo vs chemo alone in hormone sensitive advanced prostate cancer

    Publisert: 17.2.2022

  11. Episode 153: Overview of PARP inhibition in prostate cancer

    Publisert: 10.2.2022

  12. Episode 152: The Uromigos Paper of the Month - Zr-Pembrolizumab PET Imaging

    Publisert: 7.2.2022

  13. Episode 151: Bladder Cancer ESMO Guidelines update

    Publisert: 31.1.2022

  14. Episode 150: Comparing the quality of life data in renal trials

    Publisert: 24.1.2022

  15. Episode 149: Treatment-free survival for ipilimumab and nivolumab

    Publisert: 28.12.2021

  16. Episode 148: The Uromigos Paper of the Month - Stereotactic radiotherapy for advanced renal cancer

    Publisert: 21.12.2021

  17. Episode 147: Renal Cancer Christmas Special

    Publisert: 17.12.2021

  18. Episode 146: Bladder Cancer Christmas Special

    Publisert: 13.12.2021

  19. Episode 145: Prostate Cancer Christmas Special

    Publisert: 6.12.2021

  20. Episode 144: Pembrolizumab for bladder cancer

    Publisert: 2.12.2021

13 / 21

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Visit the podcast's native language site